Royal Hobart Hospital, TAS, Australia   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Hobart Australia (1804)

Organization Overview

First Clinical Trial
2004
NCT00500669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Royal Hobart Hospital | Royal Hobart Hospital Research Foundation (funding source)

Active Ingredients

Drugs in Phase 3 Trials (3)

hydroxyethyl starch (voluven) (1 trial)

povidone-iodine (betadine) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (1)

vitamin d3 (1 trial)

Drugs in Phase 1 Trials (1)

ropivacaine (naropin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Hernia (Phase 1)

Hernia, Inguinal (Phase 1)

Infections (Phase 2)

Recurrence (Phase 3)

Respiratory Tract Infections (Phase 2)

Varicose Veins (Phase 3)

Vitamin D Deficiency (Phase 2)

Wound Infection (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5